Thomas Hohman, PhD
Thomas Hohman, PhD was formerly Head of Retina Discovery and Vice President of Retina Translation Medicine at Allergan, where he was responsible for discovering and advancing new treatments for retinal diseases. Prior to retiring, his efforts at Allergan focused on identifying biomarkers and methods quantifying retina functional changes that predict disease progression. These efforts formed the basis for clinical interventional studies of novel treatments for exudative age related macular degeneration and geographic atrophy. Prior to his tenure at Allergan, Dr. Hohman held leadership positions at Alcon Research as VP of Retinal Research and Development, and at Novartis as Disease Area Section Head for Ophthalmology Clinical Research and Development. Dr. Hohman has extensive experience in identification and assessment of licensing opportunities in multiple therapeutic areas in addition to ophthalmology, such as cardiovascular, metabolic diseases, endocrinology, urology and primary care.
Dr. Hohman earned his Ph.D. at the University of California at Los Angeles and completed fellowships at the National Heart Blood and Lung Institute, as well as the National Eye Institute, NIH before beginning his career in drug development at Wyeth-Ayerst, Pharmacia, Novartis, Alcon and Allergan.